Portfolio company
Vanquish Oncology
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This drug development company produces small-molecule therapeutics that trigger cancer cell death for patients with unmet or underserved oncological needs.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Scorpion Therapeutics
This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.
MyCural Therapeutics
This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.
Chromacure
This company develops small molecule therapeutics for oncology patients to address unmet clinical needs in cancer treatment.
Sentinel Oncology
The company develops small molecule drug candidates to treat cancers and rare brain disorders for the pharmaceutical and biotechnology sectors.
Vanqua Bio
This biopharmaceutical firm develops small-molecule therapies for patients with neurodegenerative conditions including Parkinson's disease, Alzheimer's and Gaucher disease.
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
1200 Pharma
This biotechnology firm develops small molecule therapies and drug intellectual property for the treatment of cancer patients.
Shenandoah
This biotechnology company develops chemical inducers of proximity to rewire cancer drivers into signals that trigger cell death for oncology patients.